XML 55 R45.htm IDEA: XBRL DOCUMENT
v3.23.2

Collaboration and Licensing Agreements - Narrative (Details) $ in Thousands, $ in Millions, ¥ in Billions | 1 Months Ended | 3 Months Ended | 6 Months Ended | 68 Months Ended |  |  |  |  |
--- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Mar. 31, 2018 USD ($) | Dec. 31, 2017 USD ($) | Nov. 30, 2017 USD ($) | Jun. 30, 2015 USD ($) | Jun. 30, 2023 USD ($) | Jun. 30, 2022 USD ($) | Jun. 30, 2023 USD ($) | Jun. 30, 2023 CAD ($) | Jun. 30, 2022 USD ($) | Jun. 30, 2023 USD ($) | Jul. 31, 2023 USD ($) | Jun. 30, 2023 JPY (¥) | Apr. 30, 2023 USD ($) | Oct. 31, 2022 USD ($) | Apr. 30, 2022 USD ($) payment_tranche
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Total revenues |  |  |  |  | $ 22,333 | $ 2,526 | $ 33,702 |  | $ 2,994 |  |  |  |  |  |
Licensing revenue |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Total revenues |  |  |  |  | 764 | 10 | 776 |  | 14 |  |  |  |  |  |
Product supply revenue |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Total revenues |  |  |  |  | 3,260 | 952 | 3,262 |  | 966 |  |  |  |  |  |
2017 KKC Agreement | Licensing revenue |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Total revenues |  |  |  |  |  |  |  |  |  | $ 20,000 |  |  |  |  |
2017 KKC Agreement | Product supply revenue |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Total revenues |  |  |  |  | 3,300 | 952 | 3,300 |  | 966 |  |  |  |  |  |
KKC | 2017 KKC Agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront license fees |  |  | $ 30,000 |  |  |  |  |  |  |  |  |  |  |  |
Potential development milestones |  |  | $ 55,000 |  |  |  |  |  |  |  |  |  |  |  |
Potential commercialization milestones |  |  |  |  | 58,800 |  | 58,800 |  |  | 58,800 |  | ¥ 8.5 |  |  |
Fee receivable for reduction in royalty rate |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 40,000
Number of payment tranches for fee receivable for reduction in royalty rate | payment_tranche |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 2
KKC | 2017 KKC Agreement | Licensing revenue |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Proceeds from milestone payments |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 35,000 |
Fosun Pharma | Fosun Agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Potential development milestones |  |  |  |  | 3,000 |  | 3,000 |  |  | 3,000 |  |  |  |  |
Upfront payment received |  | $ 12,000 |  |  |  |  |  |  |  |  |  |  |  |  |
Potential development and commercialization milestones |  |  |  |  |  |  | $ 113,000 |  |  |  |  |  |  |  |
Threshold percentage of net sales for tiered royalties |  |  |  |  |  |  | 20.00% | 20.00% |  |  |  |  |  |  |
Fosun Pharma | Fosun Agreement | Subsequent event |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Proceeds from milestone payments |  |  |  |  |  |  |  |  |  |  | $ 2,000 |  |  |  |
Knight | Knight Agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Potential development milestones |  |  |  |  | 700 |  | $ 700 |  |  | 700 |  |  |  |  |
Upfront payment received | $ 2,300 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Potential development and commercialization milestones |  |  |  |  |  |  | 16,700 | $ 22.2 |  |  |  |  |  |  |
METiS Therapeutics Inc | Licensing revenue |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Total revenues |  |  |  |  | 800 |  | 800 |  |  |  |  |  |  |  |
Proceeds from milestone payments |  |  |  |  |  |  |  |  |  |  |  |  | $ 243,000 |  |
Upfront payment |  |  |  |  |  |  |  |  |  |  |  |  | $ 800 |  |
AstraZeneca | AZ Termination Agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of royalty revenue |  |  |  | 10.00% |  |  |  |  |  |  |  |  |  |  |
Percentage of non-royalty revenue |  |  |  | 20.00% |  |  |  |  |  |  |  |  |  |  |
Maximum potential payment per agreement |  |  |  | $ 75,000 |  |  |  |  |  |  |  |  |  |  |
Aggregate cost of revenue recognized |  |  |  |  | 18,300 |  | 18,300 |  |  | 18,300 |  |  |  |  |
Aggregate amount paid |  |  |  |  | 16,400 |  | 16,400 |  |  | $ 16,400 |  |  |  |  |
Cost of revenue |  |  |  |  | $ 1,900 | $ 200 | $ 3,000 |  | $ 300 |  |  |  |  |  |

X
- Definition Collaboration And Licensing Agreements, Upfront License Fees + References No definition available. + Details
Name: | ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFees
Namespace Prefix: | ardx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Collaborative Arrangement, Fee Receivable For Reduction In Royalty Rate + References No definition available. + Details
Name: | ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRate
Namespace Prefix: | ardx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Collaborative Arrangement, Fee Receivable For Reduction In Royalty Rate, Number Of Payment Tranches + References No definition available. + Details
Name: | ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRateNumberOfPaymentTranches
Namespace Prefix: | ardx_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Collaborative Arrangement, Potential Commercialization Milestones + References No definition available. + Details
Name: | ardx_CollaborativeArrangementPotentialCommercializationMilestones
Namespace Prefix: | ardx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Represents the amount of future development and commercialization milestone under collaborative arrangements. + References No definition available. + Details
Name: | ardx_CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones
Namespace Prefix: | ardx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Collaborative Arrangement, Potential Development Milestones + References No definition available. + Details
Name: | ardx_CollaborativeArrangementPotentialDevelopmentMilestones
Namespace Prefix: | ardx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Collaborative Arrangement, Potential Payment Per Termination Agreement, Maximum + References No definition available. + Details
Name: | ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum
Namespace Prefix: | ardx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Cost of revenue, aggregate amount recognized. + References No definition available. + Details
Name: | ardx_CostOfRevenueAggregateAmountRecognized
Namespace Prefix: | ardx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Payments of uncharged license fees, aggregate amount paid. + References No definition available. + Details
Name: | ardx_PaymentsOfUnchargedLicenseFeesAggregateAmountPaid
Namespace Prefix: | ardx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Represents percentage of non-royalty revenue. + References No definition available. + Details
Name: | ardx_PercentageOfNonRoyaltyRevenue
Namespace Prefix: | ardx_
Data Type: | dtr-types1:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents percentage of royalty revenue. + References No definition available. + Details
Name: | ardx_PercentageOfRoyaltyRevenue
Namespace Prefix: | ardx_
Data Type: | dtr-types1:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Revenue, Remaining Performance Obligation, Variable Consideration Amount + References No definition available. + Details
Name: | ardx_RevenueRemainingPerformanceObligationVariableConsiderationAmount
Namespace Prefix: | ardx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Represents the threshold percentage of net sales for tiered royalties. + References No definition available. + Details
Name: | ardx_ThresholdPercentageOfSalesForTieredRoyalties
Namespace Prefix: | ardx_
Data Type: | dtr-types1:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1 + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2 + Details
Name: | us-gaap_ContractWithCustomerLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The aggregate cost of goods produced and sold and services rendered during the reporting period. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2 + Details
Name: | us-gaap_CostOfRevenue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Cash received from licensees for license fees during the current period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25 + Details
Name: | us-gaap_ProceedsFromLicenseFeesReceived
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_LicenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=ardx_ProductSupplyRevenueMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=ardx_KyowaKirinCo.LtdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=ardx_ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ardx_LicenseAgreementDevelopmentCommercializationDistributionInChinaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=ardx_KnightTherapeuticsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ardx_LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=ardx_METiSTherapeuticsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=ardx_AstrazenecaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ardx_AstraZenecaTerminationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |